ARTICLE | Company News
AmorChem, Hopital Maisonneuve-Rosemont deal
June 30, 2014 7:00 AM UTC
Life science VC fund AmorChem partnered with the hospital and its tech transfer arm Univalor to discover inhibitors of semaphorin 3A (SEMA3A) to treat diabetic macular edema (DME). AmorChem made an u...